Clinical reference Biomarker Directory
Back to directory

Alpha-Galactosidase

Established

Alpha-galactosidase deficiency is diagnostic for Fabry disease, a lysosomal storage disorder.

Also known as Alpha-Gal A GLA enzyme
In plain language

This enzyme breaks down fatty substances in cells. When it's missing or very low, it causes Fabry disease, a rare inherited condition. The blood test works well for diagnosing affected men, but women who carry the gene often need a genetic test instead, since their enzyme levels can look normal despite carrying the disease gene.

Biomarker & context

Alpha-galactosidase A (α-Gal A) is a lysosomal enzyme that breaks down glycosphingolipids. Deficient activity causes Fabry disease, an X-linked lysosomal storage disorder leading to progressive kidney, heart, and brain damage.

What it indicates

Markedly deficient α-Gal A activity (typically <1% in classic disease) in a male patient is diagnostic for Fabry disease. Enzyme testing is unreliable in female carriers/patients, who can have disease-causing GLA gene mutations with normal enzyme activity due to X-inactivation patterns.

Diagnosis & clinical testing

Measured via dried blood spot (newborn screening), plasma, or leukocyte assay; deficiency (<0.016 U/L in one reference assay) is diagnostic in males. Because enzyme testing misses many affected females, GLA gene sequencing is required for accurate diagnosis in women.

Guiding treatment

Confirmed Fabry disease patients are candidates for enzyme replacement therapy; family members of an affected patient (especially female relatives) should undergo genetic testing rather than relying on enzyme activity alone.

Clinical significance

Diagnostic in affected males; unreliable in female carriers, who require genetic testing instead.

References
  1. Mayo Clinic Laboratories. (2025). Alpha-Galactosidase, Serum — Test Overview.
  2. HRSA. (2024). Fabry Disease — Newborn Screening.